BIOC | Biocept, Inc. | [NASD]
Index- P/E- EPS (ttm)-29.10 Insider Own- Shs Outstand1.47M Perf Week-67.52%
Market Cap3.17M Forward P/E- EPS next Y-19.50 Insider Trans- Shs Float1.47M Perf Month-72.52%
Income-37.00M PEG- EPS next Q- Inst Own10.10% Short Float / Ratio0.53% / 0.06 Perf Quarter-86.67%
Sales6.60M P/S0.48 EPS this Y-890.30% Inst Trans- Short Interest0.01M Perf Half Y-90.81%
Book/sh4.13 P/B0.52 EPS next Y38.10% ROA- Target Price- Perf Year-94.74%
Cash/sh4.63 P/C0.47 EPS next 5Y40.00% ROE- 52W Range2.10 - 47.70 Perf YTD-86.42%
Dividend- P/FCF- EPS past 5Y- ROI-281.90% 52W High-95.47% Beta0.96
Dividend %- Quick Ratio1.90 Sales past 5Y38.50% Gross Margin- 52W Low2.86% ATR1.44
Employees50 Current Ratio2.10 Sales Q/Q-96.50% Oper. Margin- RSI (14)21.52 Volatility37.45% 21.87%
OptionableYes Debt/Eq0.83 EPS Q/Q-209.10% Profit Margin- Rel Volume2.38 Prev Close2.32
ShortableYes LT Debt/Eq0.42 EarningsMay 10 AMC Payout- Avg Volume132.83K Price2.16
Recom3.00 SMA20-67.66% SMA50-74.38% SMA200-88.24% Volume316,732 Change-6.90%
Date Action Analyst Rating Change Price Target Change
Nov-14-17Reiterated Chardan Capital Markets Buy $2.50 → $1.50
Jun-02-17Initiated Chardan Capital Markets Buy $2.50
Jun-06-16Initiated ROTH Capital Buy $1.20
Aug-19-15Initiated H.C. Wainwright Buy $4
Jun-03-14Initiated Aegis Capital Buy $16
May-24-23 08:39PM
May-17-23 08:00AM
May-12-23 06:02AM
May-10-23 04:05PM
Apr-19-23 01:28PM
04:10PM Loading…
Apr-17-23 04:10PM
Mar-24-23 08:00AM
Mar-01-23 08:00AM
Jan-31-23 07:54AM
Jan-06-23 06:55AM
Dec-25-22 12:06PM
Nov-21-22 04:05PM
Nov-18-22 08:00AM
Nov-16-22 08:00AM
Nov-10-22 04:05PM
08:00AM Loading…
Oct-19-22 08:00AM
Oct-17-22 08:00AM
Oct-14-22 08:00AM
Oct-06-22 08:00AM
Aug-31-22 04:31PM
Aug-22-22 04:15PM
Aug-16-22 08:00AM
Jun-27-22 08:00AM
Jun-22-22 07:30AM
Jun-07-22 08:00AM
May-23-22 04:05PM
May-16-22 04:05PM
Apr-08-22 04:05PM
Apr-06-22 08:00AM
Mar-31-22 06:15PM
08:00AM Loading…
Mar-18-22 08:00AM
Mar-08-22 08:17AM
Mar-04-22 08:00AM
Feb-22-22 04:17PM
Feb-18-22 04:54AM
Feb-16-22 04:05PM
Feb-10-22 08:17AM
Jan-21-22 08:00AM
Jan-07-22 09:40AM
Jan-04-22 08:00AM
Dec-09-21 08:17AM
Dec-03-21 06:49AM
Nov-22-21 01:56PM
Nov-18-21 02:45PM
Nov-15-21 04:05PM
Nov-09-21 08:17AM
Nov-08-21 08:00AM
Oct-06-21 08:00AM
Sep-29-21 01:28PM
Sep-22-21 08:17AM
Sep-21-21 08:17AM
Sep-07-21 08:00AM
Aug-31-21 08:00PM
Aug-22-21 08:17AM
Aug-19-21 11:37AM
Aug-17-21 11:22AM
Aug-16-21 04:05PM
Aug-09-21 08:00AM
Aug-03-21 08:17AM
Jul-21-21 08:17AM
Jul-20-21 08:17AM
Jul-19-21 08:00AM
Jul-06-21 08:27AM
Jun-28-21 08:05AM
Jun-22-21 08:17AM
Jun-15-21 08:17AM
Jun-09-21 08:37AM
Jun-03-21 08:00AM
Jun-02-21 04:05PM
May-12-21 04:05PM
May-05-21 08:00AM
Apr-28-21 08:17AM
Apr-21-21 08:17AM
Apr-14-21 08:05AM
Apr-07-21 04:05PM
Apr-01-21 05:00PM
Mar-30-21 08:06AM
Mar-29-21 04:32PM
Mar-27-21 04:18AM
Mar-22-21 08:00AM
Mar-16-21 11:41AM
Mar-09-21 07:00AM
Mar-03-21 04:05PM
Mar-02-21 11:45AM
Feb-23-21 12:35PM
Feb-16-21 08:00AM
Feb-03-21 08:00AM
Feb-02-21 04:05PM
Jan-23-21 02:03AM
Jan-12-21 08:00AM
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.